CorMedix Inc (NASDAQ:CRMD – Get Free Report) shares crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $7.86 and traded as high as $8.09. CorMedix shares last traded at $7.94, with a volume of 1,130,265 shares changing hands.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $15.00 target price on shares of CorMedix in a research report on Monday, October 19th. Oppenheimer began coverage on CorMedix in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $15.00 price target on the stock. Royal Bank Of Canada raised their target price on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Finally, Weiss Ratings upgraded CorMedix from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.
Get Our Latest Report on CorMedix
CorMedix Stock Up 2.5%
CorMedix (NASDAQ:CRMD – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.05. CorMedix had a net margin of 40.49% and a return on equity of 40.52%. The business had revenue of $101.93 million during the quarter, compared to the consensus estimate of $96.04 million. Sell-side analysts predict that CorMedix Inc will post 0.54 earnings per share for the current year.
Institutional Investors Weigh In On CorMedix
Hedge funds have recently modified their holdings of the company. Kestra Advisory Services LLC increased its holdings in shares of CorMedix by 142.9% during the 1st quarter. Kestra Advisory Services LLC now owns 10,200 shares of the company’s stock worth $69,000 after buying an additional 6,000 shares during the last quarter. Summit Securities Group LLC purchased a new position in CorMedix in the 1st quarter worth approximately $70,000. Quantbot Technologies LP purchased a new position in shares of CorMedix in the second quarter valued at $85,000. Allworth Financial LP purchased a new position in CorMedix in the 2nd quarter valued at about $88,000. Finally, Stoneridge Investment Partners LLC purchased a new position in CorMedix in the 2nd quarter valued at about $99,000. 34.18% of the stock is owned by institutional investors and hedge funds.
CorMedix Company Profile
CorMedix Inc is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat life-threatening infections and inflammatory conditions. The company’s lead product is DefenCath, a catheter-lock solution containing taurolidine and citrate.
DefenCath is approved by the U.S. Food and Drug Administration for use in adult patients with kidney failure who are receiving chronic hemodialysis through a central venous catheter. It is intended to reduce the risk of catheter-related bloodstream infections, a significant complication for patients who depend on long-term vascular access.
Further Reading
- Five stocks we like better than CorMedix
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
